Drugs / Tarperprumig
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04631562 | Jan 2021 → Sep 2022 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07160608 | Nov 2025 → Oct 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05565092 | Feb 2023 → Jan 2024 | sickle cell disease | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tarperprumig | “Tarperprumig (ALXN1820), a novel humanized bispecific antibody, binds properdin and albumin and is being developed to treat complement-mediated diseases.” PMID 40134111 ↗ Apr 2025 |
| Known as | ALXN1820 | “Tarperprumig (ALXN1820), a novel humanized bispecific antibody, binds properdin and albumin and is being developed to treat complement-mediated diseases.” PMID 40134111 ↗ Apr 2025 |
| Action | Inhibit | “Tarperprumig was well tolerated and completely inhibited the AP in healthy adults.” PMID 40134111 ↗ Apr 2025 |
| Modality | Monoclonal antibody | — CHEMBL5315009 ↗ |
| Route | Subcutaneous | “single doses of tarperprumig were administered via subcutaneous (SC) injection” PMID 40134111 ↗ Apr 2025 |